➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
McKesson
Harvard Business School
Merck
McKinsey

Last Updated: March 4, 2021

DrugPatentWatch Database Preview

Remimazolam besylate - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for remimazolam besylate and what is the scope of patent protection?

Remimazolam besylate is the generic ingredient in one branded drug marketed by Acacia and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Remimazolam besylate has fifty-three patent family members in twenty-four countries.

Summary for remimazolam besylate
International Patents:53
US Patents:10
Tradenames:1
Applicants:1
NDAs:1
Bulk Api Vendors: 14
Patent Applications: 8
What excipients (inactive ingredients) are in remimazolam besylate?remimazolam besylate excipients list
DailyMed Link:remimazolam besylate at DailyMed

US Patents and Regulatory Information for remimazolam besylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acacia BYFAVO remimazolam besylate POWDER;INTRAVENOUS 212295-001 Oct 6, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Acacia BYFAVO remimazolam besylate POWDER;INTRAVENOUS 212295-001 Oct 6, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Acacia BYFAVO remimazolam besylate POWDER;INTRAVENOUS 212295-001 Oct 6, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Acacia BYFAVO remimazolam besylate POWDER;INTRAVENOUS 212295-001 Oct 6, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Acacia BYFAVO remimazolam besylate POWDER;INTRAVENOUS 212295-001 Oct 6, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Acacia BYFAVO remimazolam besylate POWDER;INTRAVENOUS 212295-001 Oct 6, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Harvard Business School
Merck
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.